No one ever climbed the industry ladder without getting some help along the way. And for women, including many of the accomplished top performers in this group, that can be especially important. Maybe it was an encouraging nudge for a bright young scientist or a willing mentor for a rising company player--but virtually everyone in this year's group of top women in biotech benefited from a higher-up's helping hand.
Now, these women are re-gifting that upward boost to the next generation of leaders. Some are actively involved in nonprofit groups aiming to inspire women in business. Others single out promising younger women who might benefit from their guidance and experienced counsel.
This year's Class of 2013 includes entrepreneurs running biotechs, raising cash and advancing new drugs in the clinic. Read the full report >>
Being an R&D chief at a major biopharma company in today's environment of major research cutbacks, patent expirations and pressure from investors to speed new drugs to market is no easy task--and that's why the world's top drug research gurus are bringing in the big bucks.
We sifted through proxy statements and other public documents for the financial details on pay for some of the most powerful R&D players in the industry. Combined, these 15 highest-paid R&D execs earned about $144.3 million in 2012, compared with $69.1 million in 2011, a 109% increase.
One man's compensation fueled that spectacular rise. Read the full report >>
The stats on Phase III success rates aren't good. About half end in failure--and that's after developers have had a chance to do some careful testing in humans. It's no wonder, then, that late-stage failures continue to inflict some punishing damage on the world's largest R&D organizations--which in most cases are still laboring to overcome the arrival of the patent cliff.
Editor-in-Chief John Carroll singled out what he considers the most significant Phase III setbacks of the year (so far). They were selected not just because they damaged or destroyed estimates on peak sales, but because they also reflected on the companies involved, influenced their research strategies or raised questions about a disease initiative that had grabbed the attention of everyone in the field. Read the report >>
POPULAR COMMENT THREADS
Starting this January, FierceBiomarkers is merging with its sister publication, FierceDiagnostics. FierceDiagnostics will retain its name and brand, but coverage will expand to include the use of biomarkers as they relate to the broader diagnostics industry.
African-American women who have high levels of a particular protein may be at risk for more aggressive breast cancer and poorer outcomes, according to new research from a Georgia State University study.
A team of investigators at the University of Queensland in Australia says it has found an inflammatory protein called PAR2 that builds up in the fat tissue of obese humans and rodents.
Biomarker testing can play in an important role in detecting cancer early and choosing the correct course of treatment, and it can be critical in dealing with deadly, fast-spreading diseases like lung cancer. China has keyed into its utility, with non-small cell lung cancer (NSCLC) biomarker testing already prevalent throughout the country, a new report says.
Researchers have been unable to determine why some depression patients respond better than others to the class of drugs that includes Prozac, Zoloft and Celexa. Now a team has uncovered a gene that may act as a biomarker for this type of patient, potentially helping to match the drug with the patient.
Researchers often struggle to validate their cancer biomarker findings due to a lack of reproducible methods to measure predictive proteins. Now, investigators believe they've discovered a way to measure the entire human repertoire of proteins.
From Our Sister Sites
Two years after a stinging rejection at the hands of the same committee, Bristol-Myers Squibb and AstraZeneca got a warmer reception for their diabetes drug dapagliflozin, winning a recommendation from an FDA advisory panel and brightening their odds of approval for the once-rebuffed therapy.
Earlier this fall, Given Imaging faced down restive shareholder Discovery Group, which urged the Israeli maker of the PillCam endoscopic camera to explore a sale. Now that Covidien will snatch up the company for $860 million, the activist investor has decided to move on.